Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension
Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension
复制标题
DOI:
10.1016/j.healun.2012.02.025
复制
发表时间:
2012-07-01
影响因子:
8.9
通讯作者:
Lang, Irene M.
中科院分区:
文献类型:
--
作者:
Sadushi-Kolici, Roela;Skoro-Sajer, Nika;Lang, Irene M.
Randomized controlled trials have resulted in improved outcomes in pulmonary arterial hypertension; however, they are biased by stringent inclusion criteria, pre-specified patient sub-sets, and study durations. In addition, common practice is to start oral therapies ahead of the more potent and titratable prostanoid therapies, despite advanced disease states at diagnosis. The objectives of our prospective registry were to evaluate long-term effects on functional class, 6-minute walking distance, hemodynamics, and survival, and also long-term tolerability of first-line sub-cutaneous treprostinil, a prostacyclin analog, in patients with severe pulmonary hypertension.METHODS: Data were collected from patients with functional class III/IV pre-capillary pulmonary hypertension (Dana Point groups 1 and 4; mean right arterial pressure >= 10 mmHg, and/or cardiac index 6 months, survival rates were 57% at 9 years.CONCLUSION: First-line treatment of severe pre-capillary pulmonary hypertension with sub-cutaneous treprostinil is safe and efficacious over many years. If up-titration beyond 6 months is tolerated, effective doses are reached and outcomes are good. J Heart Lung Transplant 2012;31:735-43 (C) 2012 International Society for Heart and Lung Transplantation. All rights reserved.